HEM Pharmaceuticals Corp regulatory update

HEM Pharmaceuticals Corp. The company (Philadelphia) received Orphan Drug designation for its Ampligen poly I:poly C12U treatment for chronic fatigue syndrome and for invasive malignant melanoma. Amp...